Year |
Citation |
Score |
2023 |
Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Modi A, Rokita JL, Patel K, Lane MV, Zhang B, Zhong C, Ennis B, Miller DP, ... ... Rathi KS, et al. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Biorxiv : the Preprint Server For Biology. PMID 38106022 DOI: 10.1101/2023.12.06.570390 |
0.359 |
|
2022 |
Krytska K, Casey CE, Pogoriler J, Martinez D, Rathi KS, Farrel A, Berko ER, Tsang M, Sano RR, Kendsersky N, Erickson SW, Teicher BA, Isse K, Saunders L, Smith MA, et al. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma. Cancer Research Communications. 2: 616-623. PMID 36381237 DOI: 10.1158/2767-9764.crc-22-0137 |
0.33 |
|
2021 |
Dang MT, Gonzalez MV, Gaonkar KS, Rathi KS, Young P, Arif S, Zhai L, Alam Z, Devalaraja S, To TKJ, Folkert IW, Raman P, Rokita JL, Martinez D, Taroni JN, et al. Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality. Cell Reports. 34: 108917. PMID 33789113 DOI: 10.1016/j.celrep.2021.108917 |
0.319 |
|
2021 |
Shields CE, Potlapalli S, Cuya-Smith SM, Chappell SK, Chen D, Martinez D, Pogoriler J, Rathi KS, Patel SA, Oristian KM, Linardic CM, Maris JM, Haynes KA, Schnepp RW. Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Molecular Oncology. PMID 33523558 DOI: 10.1002/1878-0261.12914 |
0.307 |
|
2020 |
Lopez G, Conkrite KL, Doepner M, Rathi KS, Modi A, Vaksman Z, Farra L, Hyson E, Noureddine M, Wei JS, Smith MA, Asgharzadeh S, Seeger R, Khan JS, Guidry Auvil JM, et al. Somatic structural variation targets neurodevelopmental genes and identifies as a tumor suppressor in neuroblastoma. Genome Research. PMID 32796005 DOI: 10.1101/Gr.252106.119 |
0.316 |
|
2020 |
McDonald JT, Stainforth R, Miller J, Cahill T, da Silveira WA, Rathi KS, Hardiman G, Taylor D, Costes SV, Chauhan V, Meller R, Beheshti A. NASA GeneLab Platform Utilized for Biological Response to Space Radiation in Animal Models. Cancers. 12. PMID 32045996 DOI: 10.3390/Cancers12020381 |
0.41 |
|
2020 |
Nabbi A, Sun P, Sumedha S, Zhu K, Yang SYC, Paulson JN, Kool M, Rathi K, Kalletla K, Raman P, Zhu Y, Resnick AC, Jones DTW, Jäger N, Pfister SM, et al. Abstract PR06: The immunogenomic landscape of pediatric primary solid tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-Pr06 |
0.417 |
|
2020 |
Chen D, Cox J, Annam J, Weingart M, Essien G, Rathi K, Khurana P, Cuya S, Harenza JL, Bosse K, Pilgrim A, Maris JM, Schnepp RW. Abstract B48: A LIN28B-PDZ kinase axis promotes neuroblastoma metastasis Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-B48 |
0.427 |
|
2020 |
Shields CE, Cuya SM, Chappell S, Rathi K, Patel S, Potlapalli S, Schnepp RW. Abstract A47: BMI1 constitutes a novel therapeutic vulnerability in fusion-positive rhabdomyosarcoma Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A47 |
0.422 |
|
2019 |
Raman P, Zimmerman S, Rathi KS, de Torrenté L, Sarmady M, Wu C, Leipzig J, Taylor DM, Tozeren A, Mar JC. A comparison of survival analysis methods for cancer gene expression RNA-Sequencing data. Cancer Genetics. 235: 1-12. PMID 31296308 DOI: 10.1016/J.Cancergen.2019.04.004 |
0.473 |
|
2019 |
Cuya SM, Pilgrim A, Rathi K, Chen D, Schnepp R. Abstract 3669: Defining an ELAVL1-Musashi 2 signaling cascade in neuroblastoma tumorigenesis Cancer Research. 79: 3669-3669. DOI: 10.1158/1538-7445.Sabcs18-3669 |
0.432 |
|
2019 |
Shields CE, Cuya SM, Chappell SK, Rathi K, Patel S, Potlapalli S, Schnepp RW. Abstract 3838: Targeting epigenetic regulator BMI-1 in alveolar rhabdomyosarcoma Cancer Research. 79: 3838-3838. DOI: 10.1158/1538-7445.Am2019-3838 |
0.419 |
|
2019 |
Weiner AK, Radaoui AB, Kendsersky NM, Harenza-Rokita JL, Sidoli S, Conkrite KL, Vaksman Z, Rathi K, Raman P, Martinez D, Bhatti T, Tsang M, Pawel B, Garcia BA, Maris JM, et al. Abstract 3650: Integrative mass spectrometry and RNA-sequencing identifies DLK1 as a candidate immunotherapeutic target in neuroblastoma Cancer Research. 79: 3650-3650. DOI: 10.1158/1538-7445.Am2019-3650 |
0.394 |
|
2019 |
Lenzen A, Lauing KL, Zhai L, Ladomersky E, Raman P, Rathi K, Lulla RR, Hashizume R, Wainwright DA. IMMU-01. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA Neuro-Oncology. 21: ii92-ii93. DOI: 10.1093/Neuonc/Noz036.122 |
0.304 |
|
2018 |
Raman P, Rathi K, Kalletla K, Zhu Y, Zhang B, Cros A, Nazarian J, Waanders AJ, Mueller S, Storm PB, Resnick AC. TBIO-28. DISEASEXPRESS, A CANCER DATA ANALYTICS AND VISUALIZATION TOOL FOR IDENTIFYING IMMUNOTHERAPEUTIC TARGETS IN PEDIATRIC BRAIN TUMORS AND OTHER CANCERS Neuro-Oncology. 20: i186-i186. DOI: 10.1093/Neuonc/Noy059.716 |
0.332 |
|
2017 |
Bosse KR, Raman P, Lane M, Sussman RT, Harenza JL, Martinez D, Heitzeneder S, Zhu Z, Rathi K, Randall M, Donovan L, Morrissy S, Zhelev DV, Feng Y, Hwang J, et al. Abstract 685: GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma Cancer Research. 77: 685-685. DOI: 10.1158/1538-7445.Am2017-685 |
0.433 |
|
Show low-probability matches. |